Organon (NYSE: OGN) (Organon), a global healthcare company with a focus on women’s health, has announced that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly owned subsidiary of Organon, as co-issuer (the Co-Issuer and, together with Organon, the Issuers), have closed an offering of the Issuers’ US$500 million of 6.750% senior secured notes due 2034 and US$500 million of 7.875% senior unsecured notes due 2034. Latham & Watkins LLP represented the initial purchasers in the offering, with a capital markets team led by New York partners Michael Benjamin and Benjamin Stern, with associates James Sullivan, Richard Dacher, and Monica Calce. Advice was also provided on collateral matters by New York partners Michele Penzer and Nicole Fanjul, with associates Carlos Ibarguengoitia and Michaela Bolden; on tax matters by New York partner Jiyeon Lee-Lim, with associate Shangpu (Nicholas) Sun; on FDA regulatory matters by Washington, D.C. partner Ben Haas, with associate Meryl Bartlett; and on intellectual property matters by San Diego/Bay Area partner Chris Hazuka, with associates Robert Yeh and Billy Wu.~~